CANY
BNTX icon

Caxton Associates (New York)’s BioNTech BNTX Stock Holding History

Caxton Associates (New York)’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,485
Closed -$682K – 531
2024
Q2 		$682K Buy
+8,485
New +$776K 0.02% 297

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caxton Associates (New York)'s BNTX Position: Q3 2024 in Review

Caxton Associates (New York) sold out of BioNTech (BNTX) in Q3 2024, closing a stake of 8,485 shares — an estimated $682K sold.

Caxton Associates (New York) first reported a position in BNTX in Q2 2024 and held it in 1 quarter. The position peaked at $682K in Q2 2024. 296 funds tracked by Wall St. Rank hold BNTX as of Q3 2024.

  • Caxton Associates (New York) reported no remaining BioNTech position as of Q3 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 8,485 BioNTech shares in Q3 2024, an estimated $682K.
  • Caxton Associates (New York) first reported a position in BioNTech in Q2 2024 and held it in 1 quarter.
  • Caxton Associates (New York)'s BioNTech position peaked at $682K in Q2 2024.
  • 296 funds tracked by Wall St. Rank held BioNTech as of Q3 2024.

Based on Caxton Associates (New York)'s 13F filing for Q3 2024, filed 14 Nov 2024.